1 Buti, M. et al. Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatology international 9, 243-250, doi:10.1007/s12072-015-9614-4 (2015).
2 Gish, R., Jia, J. D., Locarnini, S. & Zoulim, F. Selection of chronic hepatitis B therapy with high barrier to resistance. The Lancet. Infectious diseases 12, 341-353, doi:10.1016/s1473-3099(11)70314-0 (2012).
3 Zoulim, F. & Locarnini, S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137, 1593-1608.e1591-1592, doi:10.1053/j.gastro.2009.08.063 (2009).
4 Marcellin, P. et al. in The 65th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting (AASLD).
5 World Health Organization (WHO). Hepatitis B. Introduction. Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo20022/en/index1.html. Accessed: 03 August (2015).
6 Nelson, N. P., Easterbrook, P. J. & McMahon, B. J. Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease. Clinics in liver disease 20, 607-628, doi:10.1016/j.cld.2016.06.006 (2016).
7 Ward, J. W. & Hinman, A. R. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats. Gastroenterology 156, 297-310, doi:10.1053/j.gastro.2018.10.048 (2019).
8 Buti, M., Riveiro-Barciela, M. & Esteban, R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver international : official journal of the International Association for the Study of the Liver 38 Suppl 1, 84-89, doi:10.1111/liv.13641 (2018).
9 Cho, J. Y. et al. Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease. Gut 63, 1943-1950, doi:10.1136/gutjnl-2013-306409 (2014).
10 Hosaka, T. et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (Baltimore, Md.) 58, 98-107, doi:10.1002/hep.26180 (2013).
11 Lai, C. L. & Yuen, M. F. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology (Baltimore, Md.) 57, 399-408, doi:10.1002/hep.25937 (2013).
12 Wu, C. Y. et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. Gastroenterology 147, 143-151.e145, doi:10.1053/j.gastro.2014.03.048 (2014).
13 Chan, H. L. et al. Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA. Gastroenterology 146, 1240-1248, doi:10.1053/j.gastro.2014.01.044 (2014).
14 Boyd, A. et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. Journal of hepatology 65, 683-691, doi:10.1016/j.jhep.2016.05.014 (2016).
15 Ishida, Y. et al. Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics. Hepatology (Baltimore, Md.) 68, 473-484, doi:10.1002/hep.29891 (2018).
16 Tateno, C. et al. Chimeric mice with hepatocyte-humanized liver as an appropriate model to study human peroxisome proliferator-activated receptor-α. Toxicologic pathology 43, 233-248, doi:10.1177/0192623314544378 (2015).
17 Tateno, C. et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. The American journal of pathology 165, 901-912, doi:10.1016/s0002-9440(10)63352-4 (2004).
18 Tabuchi, A. et al. Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection: transmission experiments to chimeric mice with human liver repopulated hepatocytes. Journal of medical virology 80, 2064-2068, doi:10.1002/jmv.21320 (2008).
19 Tsuge, M. et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology (Baltimore, Md.) 42, 1046-1054, doi:10.1002/hep.20892 (2005).
20 Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 295, 65-73 (2006).
21 Chen, G. et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. The American journal of gastroenterology 101, 1797-1803 (2006).
22 Chen, C. H. et al. A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients. Hepatology international 7, 832-843, doi:10.1007/s12072-013-9440-5 (2013).
23 Ono, A. et al. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. Journal of hepatology 57, 508-514, doi:10.1016/j.jhep.2012.04.037 (2012).